Cited by 484Barrier Structure and Function StudiesDiabetes Treatment and ManagementRegulation of Appetite and Obesity

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier

Kastin, Abba J., Akerstrom, Victoria, Pan, Weihong·2002·Journal of Molecular Neuroscience

Open this paper in CoChat — free account

Abstract

Glucagon-like peptide-1 (GLP-1) reduces insulin requirement in diabetes mellitus and promotes satiety. GLP-1 in the periphery (outside the CNS) has been shown to act on the brain to reduce food ingestion. As GLP-1 is readily degraded in blood, we focused on the interactions of [Ser8]GLP-1, an analog with similar biological effects and greater stability, with the blood-brain barrier (BBB). The influx of radiolabeled [Ser8]GLP-1 into brain has several distinctive characteristics: 1. A rapid influx rate of 8.867 +/- 0.798 x 10(4) mL/g-min as measured by multiple-time regression analysis after iv injection in mice. 2. Lack of self-inhibition by excess doses of the unlabeled [Ser8]GLP-1 either iv or by in situ brain perfusion, indicating the absence of a saturable transport system at the BBB. 3. Lack of modulation by short-term fasting and some other ingestive peptides that may interact with GLP-1, including leptin, glucagon, insulin, neuropeptide Y, and melanin-concentrating hormone. 4. No inhibition of influx by the selective GLP-1 receptor antagonist exendin(9-39), suggesting that the GLP-1 receptor is not involved in the rapid entry into brain. Similarly, there was no efflux system for [Ser8]GLP-1 to exit the brain other than following the reabsorption of cerebrospinal fluid (CSF). The fast influx was not associated with high lipid solubility. Upon reaching the brain compartment, substantial amounts of [Ser8]GLP-1 entered the brain parenchyma, but a large proportion was loosely associated with the vasculature at the BBB. Finally, the influx rate of [Ser8]GLP-1 was compared with that of GLP-1 in a blood-free brain perfusion system; radiolabeled GLP-1 had a more rapid influx than its analog and neither peptide showed the self-inhibition indicative of a saturable transport system. Therefore, we conclude that [Ser8]GLP-1 and the endogenous peptide GLP-1 can gain access to the brain from the periphery by simple diffusion and thus contribute to the regulation of feeding.

Integrity signals

Registry

Crossref · 10.1385/jmn:18:1-2:07

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem
Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Glucagon-Like Peptide-1-(7–36)Amide Is Transformed to Glucagon-Like Peptide-1-(9–36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine1
Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595
Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
Gutzwiller, J., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 518
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468
Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1137 · Cited by 339
Distribution of glucagonlike peptide I (GLP‐I), glucagon, and glicentin in the rat brain: An immunocytochemical study
Jin, S.-L. C., Han, V. K. M., Simmons, J. G., Towle, A. C., Lauder, J. M., & Lund, P. K. (1988) · The Journal of Comparative Neurology · doi:10.1002/cne.902710405 · Cited by 332

Flagged first, then by citations

Show all 28 references

Sorted by citations

Items 201–300 of 484

The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases
Zhang, L., Zhang, W., & Tian, X. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2021.1924707 · Cited by 54
Effect of liraglutide on proliferation and differentiation of human adipose stem cells
Cantini, G., Franco, A. D., Samavat, J., Forti, G., Mannucci, E., & Luconi, M. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.12.021 · Cited by 54
Effects of GLP-1 receptor agonists on neurological complications of diabetes
García‐Casares, N., González-González, G., Cosme, C. D. L. C., Garzón-Maldonado, F. J., de Rojas-Leal, C., Ariza, M. J., Narváez, M., Barbancho, M. Á., García-Arnés, J. A., & Tinahones, F. J. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09807-3 · Cited by 52
A critical re‐evaluation of the specificity of action of perivagal capsaicin
Browning, K. N., Babic, T., Holmes, G. M., Swartz, E. M., & Travagli, R. A. (2013) · The Journal of Physiology · doi:10.1113/jphysiol.2012.246827 · Cited by 52
The role of gut endocrine cells in control of metabolism and appetite
Parker, H. E., Gribble, F. M., & Reimann, F. M. (2014) · Experimental Physiology · doi:10.1113/expphysiol.2014.079764 · Cited by 52
Analytical characterization and comparison of the blood–brain barrier permeability of eight opioid peptides
Dorpe, S. V., Adriaens, A., Polis, I., Peremans, K. Y., Bocxlaer, J. V., & Spiegeleer, B. M. J. D. (2010) · Peptides · doi:10.1016/j.peptides.2010.03.029 · Cited by 52
Routes for Drug Translocation Across the Blood-Brain Barrier: Exploiting Peptides as Delivery Vectors
Kristensen, M., & Brodin, B. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.04.080 · Cited by 52
PYY(3-36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice
Gerstenberg, M. K., Salinas, C. B. G., Rehfeld, J. F., Secher, A., Raun, K., & Wulff, B. S. (2018) · Neuropeptides · doi:10.1016/j.npep.2018.11.004 · Cited by 52
Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease
Yang, X., Feng, P., Ji, R., Ren, Y., Wei, W., & Hölscher, C. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2079492 · Cited by 52
Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans
Lerche, S. S., Brock, B., Rungby, J., Bøtker, H. E., Møller, N., Rodell, A. B., Bibby, B. M., Holst, J. J., Schmitz, O., & GJEDDE, A. H. (2007) · Diabetes · doi:10.2337/db07-1162 · Cited by 52
Exendin-4, a GLP-1 Receptor Agonist, Interacts with Proteins and Their Products of Digestion to Suppress Food Intake in Rats
Aziz, A. A., & Anderson, G. H. (2003) · Journal of Nutrition · doi:10.1093/jn/133.7.2326 · Cited by 52
Neurobehavioral effects of liraglutide and sitagliptin in experimental models
Kamble, M., Gupta, R., Rehan, H. S., & Gupta, L. K. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.02.003 · Cited by 51
Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice
Porter, D., Faivre, É., Flatt, P. R., Hölscher, C., & Gault, V. A. (2012) · Peptides · doi:10.1016/j.peptides.2012.03.014 · Cited by 51
Metabolic hormone action in the VTA: Reward-directed behavior and mechanistic insights
Geisler, C. E., & Hayes, M. R. (2023) · Physiology & Behavior · doi:10.1016/j.physbeh.2023.114236 · Cited by 51
Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease
Corbett, A., Williams, G. H., & Ballard, C. G. (2013) · Pharmaceuticals · doi:10.3390/ph6101304 · Cited by 50
ApoE and cerebral insulin: Trafficking, receptors, and resistance
Rhea, E. M., Raber, J., & Banks, W. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104755 · Cited by 50
Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Mayfield, K., Siskind, D., Winckel, K., Russell, A. W., Kisely, S., Smith, G., & Hollingworth, S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115625496 · Cited by 49
Glucagon, GLP-1 and Thermogenesis
González-García, I., Milbank, E., Diéguez, C., López, M., & Contreras, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143445 · Cited by 49
Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
Park, J. S., Kim, K. S., & Choi, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0106 · Cited by 49
Glucagon-Like Peptide 1 in the Brain: Where Is It Coming From, Where Is It Going?
Daniels, D., & Mietlicki‐Baase, E. G. (2018) · Diabetes · doi:10.2337/dbi18-0045 · Cited by 49
Cerebrovascular phenotypes in mouse models of Alzheimer’s disease
Szu, J. I., & Obenaus, A. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x21992462 · Cited by 49
Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases
Hölscher, C. (2022) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2022.955258 · Cited by 49
FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats
Sa‐nguanmoo, P., Tanajak, P., Kerdphoo, S., Jaiwongkam, T., Wang, X., Liang, G., Li, X., Jiang, C., Pratchayasakul, W., Chattipakorn, N., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.12.021 · Cited by 48
Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?
Mansur, R. B., Lee, Y. L., Subramaniapillai, M., Brietzke, E. M., & McIntyre, R. S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.048 · Cited by 48
Restoration of Cerebral and Systemic Microvascular Architecture in APP / PS 1 Transgenic Mice Following Treatment with Liraglutide™
Kelly, P., McClean, P. L., Ackermann, M., Konerding, M. A., Hölscher, C., & Mitchell, C. A. (2014) · Microcirculation · doi:10.1111/micc.12186 · Cited by 48
Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease
Padhi, D., & Govindaraju, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00335 · Cited by 47
The incretin system ABCs in obesity and diabetes – novel therapeutic strategies for weight loss and beyond
João, A. L., Reis, F., & Fernandes, R. (2016) · Obesity Reviews · doi:10.1111/obr.12421 · Cited by 47
GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
Zhang, Z., Zhang, Q., Tan, Y., Chen, Y., Zhou, X., Liu, S., & Yu, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149328 · Cited by 46
Neuroprotective effects of GLP-1 class drugs in Parkinson’s disease
Lv, D., Feng, P., Guan, X., Liu, Z., Li, D., Xue, C., Bai, B., & Hölscher, C. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1462240 · Cited by 46
Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis
Dixit, T. S., Sharma, A. N., Lucot, J. B., & Elased, K. M. (2013) · Physiology & Behavior · doi:10.1016/j.physbeh.2013.03.008 · Cited by 46
Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial
Basolo, A., Burkholder, J., Osgood, K., Graham, A. L., Bundrick, S. C., Frankl, J. A., Piaggi, P., Thearle, M. S., & Krakoff, J. A. (2018) · Metabolism · doi:10.1016/j.metabol.2018.03.017 · Cited by 46
Central Glucagon-like Peptide-1 Receptor Signaling via Brainstem Catecholamine Neurons Counteracts Hypertension in Spontaneously Hypertensive Rats
Katsurada, K., Nakata, M., Saito, T., Zhang, B., Maejima, Y., Nandi, S. S., Sharma, N. M., Patel, K. P., Kario, K., & Yada, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-49364-x · Cited by 46
Gut peptide regulation of food intake – evidence for the modulation of hedonic feeding
Woodward, O. R. M., Gribble, F. M., Reimann, F., & Lewis, J. E. (2021) · The Journal of Physiology · doi:10.1113/jp280581 · Cited by 46
Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease
Knezović, A., Barilar, J. O., Perhoč, A. B., Bagarić, R., Farkaš, V., Riederer, P. F., & Šalković‐Petrišić, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.027 · Cited by 45
Short‐Term and Mid‐Term Control of Type 2 Diabetes Mellitus by Laparoscopic Sleeve Gastrectomy with Ileal Interposition
TINOCO, A. C. D. A., El-Kadre, L. J., Aquiar, L., Tinoco, R. C., & Savassi–Rocha, P. R. (2011) · World Journal of Surgery · doi:10.1007/s00268-011-1188-2 · Cited by 44
Long Term Exendin-4 Treatment Reduces Food Intake and Body Weight and Alters Expression of Brain Homeostatic and Reward Markers
Yang, Y., Moghadam, A. A., Cordner, Z. A., Liang, N., & Moran, T. H. (2014) · Endocrinology · doi:10.1210/en.2014-1052 · Cited by 44
Molecular mechanisms linking type 2 diabetes mellitus and late-onset Alzheimer's disease: A systematic review and qualitative meta-analysis
Lemche, E., Killick, R., Mitchell, J., Caton, P., Choudhary, P., & Howard, J. K. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106485 · Cited by 45
Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain
McGovern, S. F. J., Hunter, K., & Hölscher, C. (2012) · Brain Research · doi:10.1016/j.brainres.2012.07.029 · Cited by 43
Novel GLP-1R/GIPR co-agonist “twincretin” is neuroprotective in cell and rodent models of mild traumatic brain injury
Tamargo, I. A., Bader, M., Li, Y., Yu, S., Wang, Y., Talbot, K., DiMarchi, R. D., Pick, C. G., & Greig, N. H. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.11.005 · Cited by 43
Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression—A Literature Review
Woo, Y. S., Lim, H. K., Wang, S., & Bahk, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186969 · Cited by 43
Pleiotropic Actions of the Incretin Hormones
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 42
Potentials of incretin‐based therapies in dementia and stroke in type 2 diabetes mellitus
Groeneveld, O. N., Kappelle, L. J., & Biessels, G. J. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12420 · Cited by 42
Single-Molecule Fluorescence Imaging of Peptide Binding to Supported Lipid Bilayers
Fox, C. B., Wayment, J. R., Myers, G. A., Endicott, S. K., & Harris, J. M. (2009) · Analytical Chemistry · doi:10.1021/ac9007682 · Cited by 42
Inhibiting receptor for advanced glycation end product (AGE) and oxidative stress involved in the protective effect mediated by glucagon-like peptide-1 receptor on AGE induced neuronal apoptosis
Chen, S., Yin, L., Zheng, X., An, F.-M., Liu, A., Wang, Y., Yao, W., & Gao, X. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.12.007 · Cited by 42
The Identification of Novel Proteins That Interact With the GLP-1 Receptor and Restrain its Activity
Huang, X., Dai, F. F., Gaisano, G., Giglou, K., Han, J., Zhang, M., Kittanakom, S., Wong, V., Li, W., Showalter, A. D., et al. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1047 · Cited by 41
Chemical modification of Class II G protein-coupled receptor ligands: Frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies
Chapter, M. C., White, C. M., DeRidder, A. M., Chadwick, W., Martin, B., & Maudsley, S. R. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.07.006 · Cited by 41
GLP-1: benefits beyond pancreas
Muscogiuri, G., Cignarelli, A., Giorgino, F., Prodram, F., Santi, D., Tirabassi, G., Balercia, G., Modica, R., Faggiano, A., & Colao, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0137-y · Cited by 41
Circulating TGF-β1 Does Not Cross the Intact Blood-Brain Barrier
Kastin, A. J., Akerstrom, V. L., & Pan, W. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:21:1:43 · Cited by 41
Self-citation
Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes: A Target Trial Emulation Study
Tang, H., Lu, Y., Donahoo, W. T., Shao, H., Shi, L., Fonseca, V. A., Guo, Y., Bian, J., & Guo, J. (2024) · Annals of Internal Medicine · doi:10.7326/m24-0329 · Cited by 40
Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss
Buller, S., & Blouet, C. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00250.2023 · Cited by 40
Obesity and Its Comorbidities: Current Treatment Options, Emerging Biological Mechanisms, Future Perspectives and Challenges
Wang, L., Wang, Q., Xiong, Y., Shi, W. F., & Xiao, Q. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s540103 · Cited by 41
Preliminary results from digestive adaptation: a new surgical proposal for treating obesity, based on physiology and evolution
Santoro, S., Velhote, M. C. P., Malzoni, C. E., Milleo, F. Q., Klajner, S., & Campos, F. G. (2006) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802006000400004 · Cited by 40
The GLP-1 analog, liraglutide prevents the increase of proinflammatory mediators in the hippocampus of male rat pups submitted to maternal perinatal food restriction
Diz-Chaves, Y., Toba, L., Fandiño, J., González-Matías, L. C., García‐Segura, L. M., & Mallo, F. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1370-7 · Cited by 39
The Role of Gasotransmitters in Gut Peptide Actions
Verbeure, W., van Goor, H., Mori, H., van Beek, A. P., Tack, J. F., & van Dijk, P. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.720703 · Cited by 39
Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia
Jain, S., & Sharma, B. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.09.007 · Cited by 39
Entero-insular axis in children with anorexia nervosa
Tomasik, P., Sztefko, K., Starzyk, J., Rogatko, I., & Szafran, Z. (2005) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2004.10.003 · Cited by 39
The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat
Hansen, H. H., Hansen, G., Paulsen, S. J., Vrang, N., Mark, M., Jelsing, J., & Klein, T. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.08.010 · Cited by 39
Blood-Brain Barrier and Feeding: Regulatory Roles of Saturable Transport Systems for Ingestive Peptides
Kastin, A. J., & Pan, W. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784705423 · Cited by 39
Self-citation
Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes
Sinclair, E. M., & Drucker, D. J. (2005) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000155379.11926.e2 · Cited by 39
Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease
Liu, W., Li, Y., Jalewa, J., Saunders-Wood, T., Lin, L., & Hölscher, C. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.08.038 · Cited by 38
Long‐acting glucagon‐like peptide‐1 receptor agonists have direct access to and effects on pro‐opiomelanocortin/cocaine‐ and amphetamine‐stimulated transcript neurons in the mouse hypothalamus
Knudsen, L. B., Secher, A., Hecksher‐Sørensen, J., & Pyke, C. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12463 · Cited by 38
Cerebral Glucose Metabolism following TBI: Changes in Plasma Glucose, Glucose Transport and Alternative Pathways of Glycolysis—A Translational Narrative Review
Gribnau, A., van Zuylen, M. L., Coles, J., Plummer, M. P., Hermanns, H., & Hermanides, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052513 · Cited by 36
Does glucagon-like peptide-1 induce diuresis and natriuresis by modulating afferent renal nerve activity?
Katsurada, K., Nandi, S. S., Sharma, N. M., Zheng, H., Liu, X., & Patel, K. P. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00028.2019 · Cited by 36
Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes
Bak, A. M., Egefjord, L., Gejl, M., Steffensen, C., Stecher, C. W., Smidt, K., Brock, B., & Rungby, J. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.600691 · Cited by 37
Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges
Tran, J., Parekh, S., Rockcole, J., Wilson, D., & Parmar, M. S. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123001 · Cited by 35
Incretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.014 · Cited by 35
Glucagon-like peptide-1 modulates synaptic transmission to identified pancreas-projecting vagal motoneurons
Wan, S., Browning, K. N., & Travagli, R. A. (2007) · Peptides · doi:10.1016/j.peptides.2007.08.016 · Cited by 34
Can dipeptidyl peptidase-4 inhibitors treat cognitive disorders?
Cheng, Q., Cheng, J., Cordato, D. J., & Gao, J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107559 · Cited by 34
Hormonal Regulation of Oxidative Phosphorylation in the Brain in Health and Disease
Głombik, K., Detka, J., & Budziszewska, B. (2021) · Cells · doi:10.3390/cells10112937 · Cited by 34
Glucagon-like peptide 1 (7–36) amide (GLP-1) and exendin-4 stimulate serotonin release in rat hypothalamus
Brunetti, L., Orlando, G., Recinella, L., Leone, S., Ferrante, C., Chiavaroli, A., Lazzarin, F., & Vacca, M. (2008) · Peptides · doi:10.1016/j.peptides.2008.04.007 · Cited by 34
New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders
Wilkins, H., & Morris, J. K. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612822666161230144517 · Cited by 34
Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury
Bader, M., Li, Y., Lecca, D., Rubovitch, V., Tweedie, D., Glotfelty, E. J., Rachmany, L., Kim, H. K., Choi, H., Hoffer, B. J., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.11.023 · Cited by 34
How gut hormones shape reward: A systematic review of the role of ghrelin and GLP-1 in human fMRI
Schulz, C., Vezzani, C., & Kroemer, N. B. (2023) · Physiology & Behavior · doi:10.1016/j.physbeh.2023.114111 · Cited by 33
Epidermal Growth Factor Receptor Transactivation Is Necessary for Glucagon-Like Peptide-1 to Protect PC12 Cells from Apoptosis
Kimura, R., Okouchi, M., Kato, T., Imaeda, K., Okayama, N., Asai, K., & Joh, T. (2012) · Neuroendocrinology · doi:10.1159/000345529 · Cited by 33
Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke
Li, Y., Wu, K., Yu, S., Tamargo, I. A., Wang, Y., & Greig, N. H. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.11.010 · Cited by 33
Gut Hormones Ghrelin, PYY, and GLP-1 in the Regulation of Energy, Balance, and Metabolism
Pérez–Tilve, D., Nogueiras, R., Mallo, F., Benoit, S. C., & Tschoep, M. H. (2006) · Endocrine · doi:10.1385/endo:29:1:61 · Cited by 33
Linking Nonalcoholic Fatty Liver Disease and Brain Disease: Focusing on Bile Acid Signaling
Ren, Z., Li, C.-X., Ma, C., Chen, D., Chen, J., Xu, W., Chen, C.-A., Cheng, F., & Wang, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113045 · Cited by 32
Targeting the intestinal L-cell for obesity and type 2 diabetes treatment
Albrechtsen, N. J. W., Kuhre, R. E., Deacon, C. F., & Holst, J. J. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.862152 · Cited by 32
Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment
Jeong, S. H., Kim, H. R., Kim, J., Kim, H., Hong, N., Jung, J. H., Baik, K., Cho, H., Lyoo, C. H., Ye, B. S., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012534 · Cited by 32
Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Mouhammad, Z. A., Vohra, R., Horwitz, A., Thein, A., Andreasen, J. R., Cvenkel, B., Williams, P. A., Azuara‐Blanco, A., & Kolko, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824054 · Cited by 32
Exendin-4 reduces tau hyperphosphorylation in type 2 diabetic rats via increasing brain insulin level
Yang, Y., Ma, D., Xu, W., Chen, F., Du, T., Yue, W., Shao, S., & Yuan, G. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.10.005 · Cited by 32
Association between use of oral hypoglycemic agents in Japanese patients with type 2 diabetes mellitus and risk of depression: A retrospective cohort study
Akimoto, H., Tezuka, K., Nishida, Y., Nakayama, T., Takahashi, Y., & Asai, S. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.536 · Cited by 31
The Glucagon-Like Peptide-1 Analogue Liraglutide Reduces Seizures Susceptibility, Cognition Dysfunction and Neuronal Apoptosis in a Mouse Model of Dravet Syndrome
Liu, S., Jin, Z., Zhang, Y., Rong, S., He, W., Sun, K., Wan, D., Huo, J., Xiao, L., Li, X., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00136 · Cited by 31
GLP-1 mediated diuresis and natriuresis are blunted in heart failure and restored by selective afferent renal denervation
Katsurada, K., Nandi, S. S., Zheng, H., Liu, X., Sharma, N. M., & Patel, K. P. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01029-0 · Cited by 31
Bile acids, bioactive signalling molecules in interoceptive gut‐to‐brain communication
Joyce, S. A., & O'Malley, D. (2022) · The Journal of Physiology · doi:10.1113/jp281727 · Cited by 32
Emerging role of GLP-1 receptor agonists in the treatment of obesity
Neff, L. M. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s6816 · Cited by 31
Glucagon-like peptide-1 and insulin synergistically activate vagal afferent neurons
Iwasaki, Y., Goswami, C., & Yada, T. (2017) · Neuropeptides · doi:10.1016/j.npep.2017.05.003 · Cited by 31
Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats
Sufiun, A., Rafiq, K., Fujisawa, Y., Rahman, A., Mori, H., Nakano, D., Kobori, H., Ohmori, K., Masaki, T., Kohno, M., et al. (2015) · Hypertension Research · doi:10.1038/hr.2014.173 · Cited by 30
Long-Lasting Exendin-4 Fusion Protein Improves Memory Deficits in High-Fat Diet/Streptozotocin-Induced Diabetic Mice
Park, K.-A., Jin, Z. H., Lee, J. Y., An, H. S., Choi, E. B., Kim, K. E., Shin, H. J., Jeong, E. A., Min, K. A., Shin, M. C., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020159 · Cited by 30
Neuroprotective Role of DPP-4 Inhibitor Linagliptin Against Neurodegeneration, Neuronal Insulin Resistance and Neuroinflammation Induced by Intracerebroventricular Streptozotocin in Rat Model of Alzheimer’s Disease
Siddiqui, N., Ali, J., Parvez, S., Najmi, A. K., & Akhtar, M. (2023) · Neurochemical Research · doi:10.1007/s11064-023-03924-w · Cited by 30
Glucagon-like peptide 1 and the brain: Central actions–central sources?
Trapp, S., & Hisadome, K. (2010) · Autonomic Neuroscience · doi:10.1016/j.autneu.2010.09.008 · Cited by 30
Peptide transport across the blood-brain barrier
Kastin, A. J., & Pan, W. (2003) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8049-7_3 · Cited by 30
Self-citation
Suppression of Food Intake by Glucagon-Like Peptide-1 Receptor Agonists: Relative Potencies and Role of Dipeptidyl Peptidase-4
Jessen, L., Aulinger, B. A., Hassel, J., Roy, K. J., Smith, E. P., Greer, T. M., Woods, S. C., Seeley, R. J., & D’Alessio, D. A. (2012) · Endocrinology · doi:10.1210/en.2012-1358 · Cited by 30
Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model
Fang, X., Du, Z., Duan, C., Zhan, S., Wang, T., Zhu, M., Shi, J., Meng, J., Zhang, X., Yang, M., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118966 · Cited by 29
Central Sfrp5 regulates hepatic glucose flux and VLDL-triglyceride secretion
Li, Y., Tian, M., Yang, M., Yang, G., Chen, J., Wang, H., Liu, D., Wang, H., Deng, W., Zhu, Z., et al. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154029 · Cited by 29
Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs
Ostroumova, O. D., Surkova, E. V., Chikh, E. V., Rebrova, E. V., & Borisov, M. S. (2018) · Diabetes Mellitus · doi:10.14341/dm9660 · Cited by 29
Prolonged Drug-Releasing Fibers Attenuate Alzheimer’s Disease-like Pathogenesis
Salles, G. N., Calió, M. L., Afewerki, S., Soares, C. P., Porcionatto, M. A., Hölscher, C., & Lobo, A. O. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b12649 · Cited by 29
Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution
Jalleh, R. J., Pham, H., Marathe, C. S., Wu, T., Buttfield, M., Hatzinikolas, S., Malbert, C., Rigda, R. S., Lange, K. M., Trahair, L. G., et al. (2020) · Nutrients · doi:10.3390/nu12071962 · Cited by 29
A Review of Perioperative Glucose Control in the Neurosurgical Population
Atkins, J. H., & Smith, D. S. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300615 · Cited by 29
Mechanisms behind GLP-1 induced weight loss
Larsen, P. J. (2008) · The British Journal of Diabetes & Vascular Disease · doi:10.1177/1474651408100525 · Cited by 28

Authors: Kastin, A. J., Akerstrom, V., & Pan, W.
Affiliations: Tulane University (US)
ORCID: Pan, Weihong
Venue: Journal of Molecular Neuroscience
Publisher: Springer Science and Business Media LLC
Published: 2002
Volume: 18
Issue: 1-2
Pages: 07-13
ISSN: 0895-8696 (ISSN-L)
DOI: 10.1385/jmn:18:1-2:07
OpenAlex: W2076140273
Cited by: 480
References: 28
Citations by year: 2026: 8 · 2025: 22 · 2024: 21 · 2023: 18 · 2022: 24 · 2021: 28 · 2020: 24 · 2019: 29 · 2018: 24 · 2017: 23 · 2016: 25 · 2015: 27 · 2014: 31 · 2013: 27 · 2012: 23
FWCI: 6.00
Type: journal article
Language: en
Open access: closed
Locations: Journal of Molecular Neuroscience (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Department of Veterans Affairs
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases (DK-54880)
Topics: Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords: glucagon-like peptide-1, blood-brain barrier, brain uptake, passive diffusion, GLP-1 receptor, exendin-9-39, satiety, food intake regulation, cerebrospinal fluid reabsorption
MeSH terms: Animals, Appetite Regulation, Blood-Brain Barrier, Brain, Cerebrovascular Circulation, Dose-Response Relationship, Drug, Food Deprivation, Glucagon, Hypothalamic Hormones, Insulin, Male, Melanins, Mice, Inbred ICR, Neuropeptide Y, Peptide Fragments, Pituitary Hormones, Protein Precursors, Leptin, Mice, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks